07:00 , May 25, 2015 |  BC Week In Review  |  Company News

Taxus Cardium, Shenzhen Qianhai Taxus Insdustry Capital Management deal

Taxus Cardium granted Shenzhen the first right to negotiate for an exclusive license to develop and commercialize three Taxus products in Asian countries. The products include Generx alferminogene tadenovec, an adenoviral vector carrying the fibroblast...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Company News

Shanxi Taxus, Taxus Cardium deal

Cardium Therapeutics Inc. changed its name to Taxus Cardium and partnered with Shanxi Taxus to promote each other's products. Under the deal, Shanxi Taxus agreed to apply "commercially reasonable efforts" to assist Taxus Cardium to...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

Excellagen regulatory update

Cardium said Centers for Medicare & Medicaid Services (CMS) issued a Q-code for reimbursement of Excellagen to treat hard to heal wounds. The code, Q4149, will become effective Jan. 1. Earlier this year, Cardium said...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Company News

Cardium, Kasiak Holding AG sales and marketing update

Cardium granted Kasiak rights to commercialize wound care product Excellagen in Germany and Switzerland. Cardium said it has submitted all information to receive CE Mark approval. The company declined to disclose financial terms. Earlier this...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Company News

Academy Medical LLC, Cardium sales and marketing update

Cardium granted Academy Medical rights to commercialize wound care product Excellagen to U.S. government medical providers, including the Veterans Administration healthcare system and military hospitals. Cardium said it does not plan to establish an internal...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Company News

Biorasi, Cardium sales and marketing update

Cardium granted bioRASI's Advanced Biosciences Research affiliate rights to commercialize wound care product Excellagen in the Commonwealth of Independent States (CIS). bioRASI is responsible for regulatory approval and will co-develop a marketing, sales and distribution...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Company News

Cardium sales and marketing update

Cardium launched Excellagen in the U.S. to manage diabetic foot ulcers and other dermal wounds. Cardium said the wholesale acquisition cost is $95 per application. The product is available as a single-use syringe of 0.5...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Company News

BL&H, Cardium sales and marketing update

Cardium granted BL&H Korean commercialization rights to Excellagen . Cardium will manufacture and supply the topical collagen-based gel matrix while BL&H will be responsible for regulatory approval. Terms were not disclosed. FDA approved the product...
07:00 , Oct 17, 2011 |  BC Week In Review  |  Clinical News

Excellagen regulatory update

FDA granted 510(k) clearance for Cardium's Excellagen to manage diabetic foot ulcers and other dermal wounds. The company did not disclose a launch timeline for the topical collagen-based gel matrix. Cardium Therapeutics Inc. (NYSE-A:CXM), San...
07:00 , Aug 8, 2011 |  BC Week In Review  |  Clinical News

Excellagen regulatory update

Cardium said last quarter it submitted supplemental information related to the process for manufacturing for Excellagen to treat dermal wounds. Cardium said the submission was a key requirement for clearance and believes that it has...